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Abstract. The present report describes an Intranasal 
Nicotine Aerosol Delivery Device (INADD) employing 
an artist's airbrush as aerosolizer and precise, elec- 
tromechanical control of spray duration. It was designed 
for the administration of controlled doses of nicotine in 
a laboratory setting and has been used successfully in 
over 30 smokers and nonsmokers of both genders. In the 
present study, nicotine was administered to 12 male 
smokers at three different doses (0.05 mg, 1.00 mg, and 
2.00 mg), and at the same dose (1 mg) on three different 
occasions. The low dose produced a minimal change in 
plasma nicotine, while the high dose produced a peak 
increment of around 16 ng/ml. The medium dose reliably 
produced a peak increment of around 8 9  ng/ml on all 
three occasions. Nicotine in plasma showed a sharp rise 
followed by a slower decline, mimicking the pattern asso- 
ciated with cigarette smoking. Physiological and bio- 
chemical responses showed significant dose-response 
relationships. Subjective reports suggested that aerosol 
dosing was somewhat aversive, but it is unclear whether 
this effect is intrinsic to the method or due to other 
factors. The device described in this report answers the 
need for a safe and easy means of controlling nicotine 
dose. Moreover, since nicotine administration via aero- 
sol is novel for both smokers and non-smokers, mini- 
mizing the contributions of behavioral tolerance and 
habituation to the dosing vehicle, it lends itself to the 
comparison of the pharmacological effects of nicotine 
between experienced and naive subjects. 
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The difficulty of controlling nicotine dose continues to be 
a limiting factor in research on cigarette smoking and 
nicotine dependence. Attempts to control dosing by 
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means of changing the nicotine available in cigarette 
smoke are confounded by the smoker's well-documented 
ability to adjust nicotine intake (behavioral compensa- 
tion) over wide differences in nicotine content or delivery 
(USDHHS 1988). Furthermore, depending on how it is 
smoked, the same cigarette can deliver varying amounts 
of nicotine to different smokers or to the same smoker 
at different times. The problem is clearly relevant to the 
understanding of nicotine dependence, as nicotine's 
psychoactive effects vary with dose low doses being asso- 
ciated with alertness and stimulation, and high doses 
with calming and sedation (Ashton et al. 1978; Warbur- 
ton and Wesnes 1978; Golding and Mangan 1982; Rose 
et al. 1983; Henningfield and Woodson 1989). 
In a review of the problem, Pomerleau et al. (198%) 
identified some of the criteria that should be met for a 
nicotine dosing method to be considered satisfactory for 
the study of cigarette smoking: 1) the method should be 
safe and easy to use; 2) specified doses should be ac- 
curately and reproducibly delivered; and 3) the pharma- 
cokinetics of the dosing method should resemble those 
of cigarette smoking, since a sharp rise in plasma nicotine 
followed by a gradual decay is the pattern believed re- 
sponsible for the unique reinforcing effects of cigarette 
smoking (Pomerleau and Pomerleau 1984). 
Although nicotine can be administered intravenously 
in precisely controlled amounts (Benowitz et al. 1982; 
Feyerabend et al. 1985), the procedure is invasive and 
requires considerable care as bioavailability is complete 
and irrevocable; typically, dosing is conducted in dedi- 
cated in-hospital research settings. At the other extreme, 
the control of dosing by delimiting smoke inhalation 
(e.g., pre-determining the parameters of puffing topog- 
raphy) is safe on an acute basis and has enjoyed some 
degree of success (Zacny and Stitzer 1986; Gilbert et al. 
1989; Pomerleau et al. 1989b; Cherek et al. 1991); fur- 
thermore, such techniques are highly acceptable to 
smokers, and the dosing kinetics are equivalent to ordi- 
nary smoking. Unfortunately, the approach does not 
lend itself to the study of either never-smokers or ex- 
smokers-groups whose investigation may shed light on 
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the na tu re  o f  n ico t ine  re in fo rcement  or  the  pers is tence o f  
a d a p t a t i o n  to nicotine.  
A b o u t  ten years  ago,  Russel l  et al. (1983) devised a 
n icot ine  nasa l  so lu t ion  technique;  a l t hough  subject ive 
effects resembled  those  p r o d u c e d  by  cigaret tes ,  n icot ine  
a b s o r p t i o n  var ied  widely.  M o r e  recently,  Perkins  et  al. 
(1986) descr ibed  the use o f  a na sa l - sp ray  p u m p  p r o c e d u r e  
to del iver  me te red  doses  o f  n icot ine  in aqueous  solut ion.  
The data for  the three  subjects  for  w h o m  nicot ine  levels 
were s ampled  sugges ted  fair ly good  con t ro l  over  dosage,  
and there  seemed to be cons is tency in dos ing  a m o n g  the 
three subjects ;  t hough  the sample  was l imited,  the rise 
and decay  o f  the  p l a s m a  nicot ine  curve resembled  the 
usual  pa t t e rn  for  c igare t te  smoking .  The  p resen t  r epo r t  
descr ibes  an  In t r anasa l  Nico t ine  Aeroso l  Del ivery  Device 
( I N A D D )  tha t  employs  an  a r t i s t ' s  a i rb rush  as aeroso l izer  
and precise, e lec t romechanica l  con t ro l  o f  sp ray  dura t ion .  
Dose - response  charac ter i s t ics  for  the I N A D D  are  de-  
scr ibed for  12 subjects,  sys temat ica l ly  showing  p l a s m a  
nicot ine  increments  as well as subject ive,  phys io logica l ,  
and b iochemica l  responses  to  n icot ine  del ivery  at  three  
different  dose  levels. The  same dose was also adminis -  
tered on three  different  occas ions  to de te rmine  whe ther  
c o m p a r a b l e  increments  in p l a s m a  n icot ine  could  be reli- 
ab ly  r ep roduced .  
Materials and methods 
Subjects, Subjects were 12 male smokers recruited from the general 
community and paid for their participation. They were required to 
be between the ages of 21 and 40, with normal body weight (BMI 
19-29), to be free from serious medical or psychiatric conditions, 
and to be using no prescription medications. Additional exclusion 
criteria were sinus conditions or upper respiratory difficulties. In 
order to obtain a distribution of subjects that would allow us to 
determine whether there were any differences between light and 
heavy smokers with respect to their ability to tolerate the procedure, 
subjects were telephone-screened using the Fagerstrom Tolerance 
Questionnaire (FTQ; Fagerstrom 1978), and an effort was made to 
include subjects across a wide range of scores. 
Apparatus. The INADD is shown in Fig. t. It consisted of a stain- 
less-steel artist's airbrush (Olympus-Medea model HP-18BC) em- 
ployed as aerosolizer, with duration of aerosol delivery determined 
by a Skinner pneumatic solenoid valve (Honeywell model V 
52DB2100) that interrupted airflow from an air compressor (Thom- 
as Industries model 600); pressure transients were measured via 
an in-line monitor (Omega model HP520). The device is an adapta- 
tion of a cocaine delivery system developed by Lukas et al. (1990); 
under FDA regulations, the administration of nicotine in this fash- 
ion qualifies as "unapproved use of an approved drug" (Kessler 
1989; p 285). Duration of airflow to the airbrush was controlled via 
a manually-adjustable solid state timing unit. To prevent accidental 
administration, two functions were required for delivery-..depression 
of an "enable" and an "administer" button. A plastic disposable 
nosepiece (Sarstadt #57.512 centrifuge tube) about 1 cm in length 
was cut open at one end and the inner wall of the other end was 
gouged out to fit snugly on the stainless steel nozzle of the airbrush. 
(The spray clutch was kept in the fully open position by a screw, 
and spray width was set so that none of the spray coated the inside 
of the plastic nosepiece.) About 150 gl of nicotine solution was 
placed in a 2 ml plastic reservoir attached to the airbrush. When a 
dose was to be administered, the subject inserted the nosepiece 
about 0.5 cm into the nostril. A dose was administered in less than 
5 s and consisted of two 50 ~tl aerosol sprays (7 psi for 1 s), one spray 
into each nostril. 
The nicotine solution for the nasal spray was prepared from 
doubly recrystallized nicotine tartrate and sterile 0.9 % saline. Accu- 
racy of specified nicotine concentrations was verified by HPLC (see 
below) prior to administration. The solution was buffered to a pH 
of 7.5 and contained menthol (0.1 mg/ml) to mask the smell of the 
nicotine. The solution was filtered through a "Milex-GS" (Milli- 
pore, Bedford, MA) filter unit (0.22 microns) in a laminar flow 
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sterile hood and aliquoted into 10 ml sterile injection bottles. The 
sterility of the solutions was confirmed by incubation studies with 
both thioglycolate and soy broth media. All components of the 
INADD that came in contact with the nicotine solution were disin- 
fected by soaking them in a 10 % Zepharin (benzalkonium) solution 
for about 3 h and rinsed thoroughly with sterile water several times 
before use. The concentrations of nicotine in spray were checked by 
spraying designated volumes into wide-mouth tubes for weighing 
and for subsequent assay by HPLC (see below). The coefficient of  
variation (CV = SD/mean x 100) for actual volume delivery and for 
nicotine delivery was less than 5 %. The reproducibility and accuracy 
of volume delivery (minimum 10 test sways) was checked every day 
prior to use. 
Heart rate and digit skin temperature were monitored using a 
Grass model 7B polygraph. Galvanic skin response was measured 
using a J&J GSR Preamplifier Model T-68. Blood pressure was 
recorded using a Vitastat Automatic Blood Pressure Monitor 
Model 900-S. A Vitalograph BreathCO device was used to deter- 
mine levels of carbon monoxide. (Calibration of physiological in- 
puts was by physical simulation, utilizing pre-set numbers of elec- 
tronic "R"  waves, known concentrations of CO, etc. ; the exception 
was blood pressure readings, whose accuracy was determined using 
manual sphygmomanometry.) All experimental sequences were 
controlled by an IBM AT computer located in the adjacent control 
room. Standardized instructions were delivered via an A M I G A  
computer equipped with a voice synthesizer; the A M I G A  was also 
used to present visual analog scale (VAS) ratings (responses ob- 
tained via computer mouse) of  desire to smoke, nausea, dizziness, 
and satisfaction compared with the usual cigarette (queried im- 
mediately after the nicotine dose). An indwelling 18-gauge catheter 
was inserted into a left antecubital vein and attached to an opaque 
1 m length of infusion-exfusion tubing that ran through a channel 
in the wall to allow unobtrusive withdrawal in the control room; 
the line was heparinized, and samples were collected in standard 
EDTA vacutainer tubes. Samples were kept on ice during the 
session, then centrifuged at 4 ° C, with the plasma stored at - 8 0  ° 
C until assayed. With the exception of the actual INADD spray 
administration, there was no subject/experimenter interaction 
during the course of a session. 
Assays. Plasma nicotine and cotinine concentrations were deter- 
mined by a slight modification of the high performance liquid 
chromatographic (HPLC) method of Hariharan et al. (1988). The 
isocratic method utilizes a C-18 reversed phase column (15 x 0.46 
cm) and a mobile phase of citric acid-phosphate buffer containing 
triethylamine at pH 4.7. The ultraviolet detection was monitored at 
256 nm. The interassay coefficient of  variation was 6.5 % for nicotine 
and 4.0% for cotinine. The detection limit of  the assay was 1.0 ng/ml 
for nicotine and 3 ng/ml for cotinine. Plasma cortisol levels were 
quantitated by competitive protein binding assay; average interas- 
say CV is 6.3% and intra-assay CV is 5.9%, with a 0.5 gg/dl limit 
of detection. 
Procedure. The protocol for this study was approved by the In- 
stitutional Review Board of the University of Michigan Medical 
School. All subjects participated in a screening session in which the 
study was explained and informed consent obtained. They were 
then familiarized with the INADD procedure via the administration 
of  two sprays of  sterile 0.9% NaC1, one to each nostril. 
The study design consisted of  five sessions, identical in format 
except for the nicotine dose administered, and scheduled 2-3 days 
apart insofar as possible. During each of  the first three sessions, 
presented in Latin square order, subjects received either an ultra- 
low dose (0.05 mg nicotine, intended to be physiologically and 
pharmacologically inert), a medium dose (1.00 mg nicotine), or a 
high dose (2.00 mg nicotine). The fourth and fifth sessions consisted 
of repetitions of  the medium dose. Thus, the design actually incor- 
porated two overlapping sub-experiments, with the first three ses- 
sions intended to test ability to achieve parametric dosing and to 
determine whether there was a linear relationship between dose 
administered and plasma levels achieved; and the three medium- 
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dose sessions designed to test ability to reproduce, within and across 
subjects, comparable nicotine levels in plasma. All sessions were run 
double-blind. 
Because of experimenter error, physiological data were not 
collected on one subject during his high-nicotine session. Conse- 
quently, his high-nicotine session was rerun following the fifth 
experimental session. Since the original high-nicotine session hap- 
pened to be his session 3, this circumstance resulted in minimal 
disruption of  the Latin square sequence. Nicotine levels were similar 
for the original and the repeat high-nicotine session; all analyses 
presented in this paper include data from the repeat session for this 
subject. 
Testing began at 0830 hours following overnight abstinence 
from smoking; compliance was assessed preliminarily by a breath 
CO reading of  < 20 ppm and later verified by baseline nicotine 
values. The subject rested quietly for 15 min after a patent line was 
established. Blood samples for nicotine and cotinine, blood pressure 
readings, and VAS responses were obtained at baseline (minute 0, 
immediately before aerosol administration) and every 5 min there- 
after until minute 30. For the administration of the nicotine dose, 
the subject placed the nosepiece into a nostril, signaled readiness, 
and took a "strong, steady sniff" for about 1 s coincident with 
delivery of the aerosol spray. Within 5 s, a second spray was 
administered to the other nostril in the same manner. The subject 
was instructed to inhibit sneezing and not to blow his nose for 5 min 
(a tissue was used to catch drainage, when necessary). After the 
dose, and when not responding to the VAS queries, the subject sat 
quietly and read. 
Data analyses. Nicotine data were subjected to a full time-course 
factorial ANOVA, with drug dose (low, medium, and high) and 
time (minutes 0, 05, 10, 15, 20, 25, and 30) as repeated measures. 
Base-to-peak scores for physiological and subjective data were 
computed and subjected to a one-way ANOVA. Trend analyses 
were included as appropriate to verify that a dose-response relation- 
ship had occurred. 
Results 
Subjects had a mean ( + SEM)  age of 24.54-5.5 years. 
Their mean weight was 75 .3 i7 .9  kg, mean height 
1.84-0.t M, and mean Body Mass Index (kg/m 2) 
23.5:52.7. The had smoked a mean of  17.54-6.1 ciga- 
rettes/day for a mean of  8.4:t: 6.4 years. Mean Fager- 
strom TQ (range 1-I 1) was 5.3 4- 2.5. 
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Fig. 2. Plasma nicotine levels (mean :t: SEM) for all sessions 
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Fig. 3. Physiological and biochemical responses (mean + SEM to parametric doses of nicotine (N= 12): base-to-peak changes in heart rate, 
skin temperature (N= 10), systolic and diastolic blood pressure, and GSR, and end-of-session changes in cortisol 
The highest baseline nicotine level of  any subject for 
any of  the five sessions was 6.2 ng/ml, indicating com- 
pliance with the overnight deprivation procedure. N o  
differences were observed between light versus heavy 
smokers in the ability to tolerate the procedure. Nicotine 
levels for all five sessions are shown for all subjects in 
Fig. 2. 
Plasma nicotine increments following parametric dosing 
procedure (sessions 1, 2, and 3) 
Time course analysis for the low-, medium-, and high- 
nicotine sessions showed highly significant effects for 
dose [F (2,20)= 37.45, P <  0.0001), time IF (5 ,50)= 21.25, 
P <  0.0001), and dose x time IF(10,100)= 6.28, P <  0.0001). 
When each of the three dosing curves was subjected to 
trend analysis, a significant linear trend was detected for 
the medium [F (1,10)= 15.70, P=0.005] and the high 
[F (1,10)=66.52, P<0.0001] doses, but not for the low 
dose. Base-to-peak changes were minimal for the low 
dose (1.6-+0.5 ng/ml), 7.9-+1.4 ng/ml for the medium 
dose, and 15.6 + 2.6 ng/ml for the high dose. With respect 
to within-subject parametric dosing, for all 12 subjects 
the lowest nicotine increment was associated with the low 
dose session and the highest with the high close session. 
The between-subjects CV for the high nicotine session 
was 57%. 
Plasma nicotine increments following dosing replicability 
procedure (sessions 2, 4, and 5) 
Time course analysis for the three medium-nicotine 
sessions showed a highly significant time effcct 
[F (6,60)=30.56, P<0.0001]. No significant effects were 
detected for dose. Mean ( +  SEM) nicotine increment was 
7.9 _+ 1.4 ng/ml for the first exposure to the medium dose, 
8.1_+1.1 to the second, and 9.8_+1.1 for the third. Be- 
tween-subject CVs for the three sessions were 63 %, 47%, 
and 38%, averaging 49%. Within-subject CVs across the 
three sessions (comparing nicotine boost over three ses- 
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sions for each subject), ranged from 5% to 52%, averag- 
ing 28%. The weight range of  the subjects was 6 2 - 8 9  kg, 
and a determination was made of whether heavier sub- 
jects achieved smaller boosts in plasma nicotine by virtue 
of having received lower doses of smoke per kilogram of 
body weight. Pearson correlation coefficients of weight 
with nicotine boost for each of the three medium nicotine 
sessions were r = - 0 . 2 7 7 ,  r = - 0 . 1 8 6 ,  and r = - 0 . 3 4 1  
(all NS). 
Physiological and biochemical effects of parametric 
doses of nicotine delivered via INADD 
Physiological and biochemical data are presented in Fig. 3. 
Physiological data are in line with the expected dose- 
related effects of  nicotine. Heart rate showed a significant 
dose-related response to nicotine [dose effect: F (2,22)= 
13.93, P<0.0001;  linear trend: F (1,11)=28.93, 
P<0.0005),  as did systolic blood pressure [dose effect: 
F (2,22) = 8.84, P <  0.005; linear trend: F (1,11) = 13.14, 
P<0.005],  diastolic blood pressure [dose effect: 
F (2,22) = 10.40, P < 0.001 ; linear trend: F (1,11) = 17.37, 
P<0.005],  and GSR [dose effect: F (2,22)=14.43, 
P<0.0001;  linear trend: F (1,11)=35.53, P<0.0001]. 
Because of  equipment problems, peripheral skin tem- 
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perature data were available for only ten subjects; tem- 
perature showed a trend towards a dose-related decrease 
[dose effect: F (2,18)=3.40, P=0.0559; linear trend: 
F (1,9) = 3.66, P = 0.0879]. 
Cortisol showed a strong secular trend downward in 
the control (0.05 mg nicotine) condition, and the values 
shown in the cortisol panel indicate the level reached at 
the 30 min end point. (Subtracting values from the con- 
trol session for each subject clearly reveals that the stim- 
ulation of cortisol by nicotine opposed the secular trend, 
and that it had not reached its full effect by the end of 
the session, at least for the high dose.) Nevertheless, 
cortisol showed a significant dose-related response to 
nicotine [dose effect: F (2,22)=4.88, P<0.05;  linear 
trend: F (1,11)=8.31, P<0.05]. 
Subjective effects of parametric doses of nicotine 
delivered via INADD 
Subjective responses to the low, medium, and high doses 
of nicotine aerosol are shown in Fig. 4. Subjects rated the 
aerosol administration as about a quarter as satisfying as 
their usual cigarette, with satisfaction decreasing as con- 
centration increased, though not significantly. There was 
a significant dose-related impact on desire to smoke, pre- 
to post-dosing [dose effect: F (2,22)= 3.44, P =  0.0503; 
linear trend: F (1,11)= 5.21, P<0.05]. There were also 
significant dose-response relationships for peak nausea 
[dose effect: F (2,22)=8.14, P<0.005; linear trend: 
F(1,11) = 15.93, P <  0.005] and peak dizziness [dose effect: 
F (2,22) = 9.03, P < 0.005; linear trend: F (1,11) = 11.03, 
P=0.01]. 
Discussion 
Plasma nicotine levels resulting from dosing using 
INADD exhibited a sharp rise followed by a gradual 
decay; the level and pattern were comparable to that 
commonly observed for cigarette smoking. Extrapola- 
tion of the pharmacodynamics of nasal nicotine to that 
of cigarette smoking, however, should be made with 
caution; although venous blood levels may look similar, 
arterial blood levels, which are believed to be more close- 
ly related to pharmacological effects, could be different. 
Though the overall pattern was similar to that ob- 
tained by Perkins et al. (1986) using a nicotine aerosol 
pump method, the plasma nicotine increments from the 
1 mg and 2 mg doses in the present study were two-thirds 
and three-quarters, respectively, of that reported by Per- 
kins. The relationship between dosing and the plasma 
nicotine rise was nearly proportional in the present 
study; in Perkins' study, the plasma nicotine response to 
the lower doses was proportional, but the response to the 
highest dose was somewhat attenuated. These minor 
discrepancies may be due to plasma nicotine data being 
available for only three subjects in Perkins' study, or they 
could come from procedural variations between the two 
procedures, e.g., the administration of two sprays within 
5 s versus ten sprays over 5 rain, resulting in a total dose 
volume of 0.1 ml in the present study versus 1.8 ml in 
Perkins's study. Moreover, the pH in Perkins's study 
(6.1) was lower than that of the present study (7.5), which 
might have diminished transfer of the highest dose in his 
study. 
Repeat administration of the medium dose in separate 
sessions produced plasma nicotine time courses that were 
not significantly different from one another, indicating 
consistency of dosing. Moreover, within the weight range 
in the present study (62-89 kg), plasma nicotine from 
aerosol dosing was not affected in any systematic way by 
body weight. These reliability results are in keeping with 
those of Perkins et at. (1989), who, in a subsequent study, 
ascertained the consistency of the aerosol pump spray 
approach on nicotine boost using a sample of three 
smokers given four doses of nicotine aerosol spaced 20 
min apart (a dose was 6 sprays over 3 rain, resulting in 
total dose volume of 1.08 ml). 
Between-subject variability in plasma nicotine was 
considerably higher than within-subject variability in the 
present study, suggesting that each subject obtained a 
characteristic nicotine boost. This is consistent with 
previous observations of  individual variability in nicotine 
pharmacokinetics (Benowitz et al. 1982; Feyerabend et 
al. 1985; Pomerleau et al. 1989b). Specifically, Benowitz 
(1991) has noted that even in the case of intravenous 
nicotine administration (where bioavailability is fully 
controlled), there can be up to fourfold differences in 
nicotine metabolism in smokers. While the level of vari- 
ability for the present aerosol dosing method is some- 
what greater than was found for intravenous nicotine 
administration procedures (see review by Pomerleau et 
al. 1989b), the difference does not necessarily reflect defi- 
cient dose control. A possible explanation is that rapid 
administration of nicotine increases the potential for 
between-subject variation in the rate of distribution, thus 
exaggerating variability in plasma nicotine levels mea- 
sured shortly after dosing. 
Physiological and biochemical effects were linearly 
related to INADD dosing. Heart rate boost and blood 
pressure increases were proportional to nicotine dose to 
a striking degree. In the only other published test of a 
similar method (Perkins et al. 1986), dosing via a nicotine 
aerosol pump resulted in nicotine-produced elevations, 
but physiological effects did not show a close correspon- 
dence to dose magnitude, with values for the inter- 
mediate and high doses overlapping (possibly because of 
the attenuated plasma nicotine increment at the highest 
dose level). In the present study, galvanic skin response, 
which reflects nicotine's general enhancement of sym- 
pathetic tone (Benowitz 1988), showed a linear relation- 
ship to nicotine dose; digit temperature, which reflects 
nicotine's vasoconstrictive actions, showed a dose related 
trend. Cortisol, which has been recently implicated in 
feedforward modulation of sensitivity to nicotine 
(Pomefleau and Pomerleau 1990b), exhibited stimulation 
that was related to the nicotine dose (overcoming the 
strong downward secular trend typical of plasma cortisol 
at this time of day; Pomerleau and Pomerleau 1990a). 
Subjective effects in the present study were significant- 
ly related to aerosol dose with respect to ratings of desire 
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to smoke, nausea, and dizziness. These findings can best 
be interpreted by comparison with values f rom a study 
of  cigarette smoke inhalation in smokers assessing some 
of the same subjective effects (Cherek et al. 1991). In 
Cherek's  study, dosing was in four intervals ranging f rom 
sham smoking, which produced no nicotine boost,  to the 
highest nicotine concentration, which yielded a plasma 
nicotine increment of  19 ng/ml: ratings of  nausea in- 
creased as a function of  nicotine dose, ranging f rom a low 
of nearly zero to a high of  about  8 % of  scale max imum 
at the highest dose (compared to 33% for the high dose. 
associated with a plasma nicotine increment of  16 ng/ml 
in the present study); ratings of  dizziness increased f rom 
a low of  about  4% to a high somewhat  more  than 30% 
(compared to 41% for the high dose in the present study). 
These results indicate that  even in subjects accustomed 
to the dosing via cigarette smoke, aversive components  
are experienced, albeit with less intensity than for the 
aerosol dosing method. Since the present procedure 
provided minimal opportuni ty  for habituat ion to the 
aversive aspects of  aerosol dosing (data were based on a 
series of  7 s p r a y ~ 2  saline sprays followed by 5 nicotine 
sprays), the finding that nicotine dosing by means of a 
novel method was more  aversive than usual cigarette 
smoking should not be particularly surprising. Whether  
smokers would adapt  to nicotine aerosol dosing after 
repeated exposure, and the degree to which such dosing 
would become pleasurable, remain to be determined. 
The approach to the delivery of  nicotine via intra- 
nasal aerosol described herein meets most  of  the require- 
ments indicated for a nicotine dosing method for study- 
ing cigarette smoking. Accuracy of  dosing was con- 
firmed, both by resulting increases in plasma nicotine 
level and by corresponding dose-related effects on known 
markers  of  nicotine's physiological and neuroendocrine 
activity. Subjective reports suggested that  aerosol dosing 
was somewhat  aversive, but  it is not clear whether this 
effect is intrinsic to the method or due to nicotine ad- 
ministration per se (cf Cherek et al. t991), or alternative- 
ly if  it was due to insufficient opportuni ty  for behavioral 
tolerance and adaptat ion to occur. The method has been 
tested in more than 30 subjects without serious ill effect. 
A recent exploration of  the subjective effects and overall 
safety of  the method was conducted in ten smokers and 
ten never-smokers (unpublished manuscript):  Non-  
smokers reported fairly intense nausea and dizziness 
(necessitating termination of  the session in three subjects) 
at doses that  produced plasma nicotine levels in the order 
of  12 ng/ml;  when dosage was reduced to produce a level 
of  7.5 ng/ml, subjective and physiological effects for 
non-smokers were similar in magnitude and duration to 
those observed for smokers receiving doses producing 
around 12 ng/ml. 
A feature of  the I N A D D  approach is that nicotine 
administration via aerosol is novel for all subjects- 
smokers as well as non-smokers- thereby minimizing the 
contributions of  behavioral  tolerance and habituat ion to 
the dosing vehicle. In addition to flexible dose manipula-  
tion, the potentially confounding contributions of  several 
thousand compounds  in tobacco smoke are eliminated. 
Thus, the method lends itself to the investigation of  the 
response to nicotine in populat ions who have never used 
nicotine as well as in those who have administered it 
extensively, providing a technological basis for systemat- 
ic explorations of  vulnerability to nicotine use and sus- 
ceptibility to nicotine dependence. These features were 
exploited in the above-mentioned examination of  dif- 
ferences in sensitivity to nicotine in smokers and never- 
smokers (unpublished manuscript).  
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